CJ Bioscience Annual Disclosure: Maintains Financial Stability with 18.6% Debt Ratio, but Continues Losses from R&D Investment
CJ Bioscience has disclosed its annual conglomerate status as part of the CJ Group. The largest shareholder is CJ CheilJedang with a 61.95% stake.
Financial position remains stable: total assets of 71.74B KRW, liabilities of 11.25B KRW, resulting in a low debt ratio of 18.6%, and cash equivalents of 10.34B KRW.
However, as an R&D-focused company, it recorded an operating loss of 24.3B KRW and a net loss of 22.84B KRW against revenue of 3.37B KRW, reflecting continued losses.
The board consists of 5 members including 3 outside directors, with committees for audit, compensation, ESG, and internal transactions.
Electronic voting is adopted, but general shareholder voting participation is low at 1.76%.
Related party transactions are minimal, and there are no circular shareholdings or large internal transactions.
[AI Summary]This is a routine annual disclosure with no events affecting shareholder value such as capital changes or share buybacks; the operating loss is an anticipated R&D investment pattern and not a short-term negative.
KOSDAQ Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]